ClinConnect ClinConnect Logo
Search / Trial NCT05312242

Introduction of MMS to Antenatal Care in Bamako, Mali

Launched by JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH · Mar 25, 2022

Trial Information

Current as of May 29, 2025

Completed

Keywords

Multiple Micronutrient Supplements (Mms) Adherence Acceptability Implementation Research Antenatal Care

ClinConnect Summary

In the past several decades, the République du Mali (Mali) has achieved reductions in both maternal mortality ratio and neonatal mortality rate. However, with an estimated 562 maternal deaths per 100,000 live births and 65.8 infant deaths per 1,000 births, substantial changes to maternal child health services will likely need to be implemented to realize the benefits of universal healthcare for mothers and children and recover from the damaging impacts of colonialism and conflict. The prevalence of low birth weight (\<2.5 kg) among children whose birth weights are known is estimated to be a...

Gender

ALL

Eligibility criteria

  • INCLUSION CRITERIA:
  • Sample Group 1: Pregnant Women
  • Potential supplementation trial participants must meet all the following criteria to be eligible for inclusion in the study:
  • 1. Age 18 years or older at screening.
  • 2. At time of enrollment, able and willing to comply with all study requirements and complete all study procedures.
  • 3. Able and willing to provide verbal informed consent to be screened for and to take part in the study.
  • 4. Intention to stay within study catchment area for study duration and willingness to give adequate locator information, as defined in site standard operating procedures (SOPs).
  • 5. Presenting for first ANC visit.
  • 6. Pregnant, as confirmed by at least one of the following:
  • 1. Uterine examination
  • 2. Urine human chorionic gonadotropin (HCG)
  • 3. Ultrasound
  • Sample Group 2: Midwives
  • Midwives who participated in delivery of the intervention will be recruited from the six health center study sites. Inclusion criteria includes the provision of verbal informed consent.
  • Sample Group 3: Pharmacists
  • Pharmacists who participated in delivery of the intervention will be recruited from the six health center study sites. Inclusion criteria includes the provision of verbal informed consent.
  • Sample Group 4: Family Members
  • Family members (e.g., male partners and mothers/mothers-in-law) will be recruited based on participation of their female family member in the study protocol. Inclusion criteria includes the provision of verbal informed consent.
  • EXCLUSION CRITERIA:
  • Sample Group 1: Pregnant Women
  • Potential supplementation trial participants who meet any of the following criteria will be excluded from the study:
  • 1. At time of enrollment, evidence of gestational age greater than 26 0/7 weeks, using one or more of the following methods: a) Uterine examination, b) First day of last normal menstrual period, and c) Ultrasound
  • 2. As determined by the site investigator, any significant uncontrolled active or chronic cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, respiratory, immunologic disorder, or infectious disease. Note: examples of uncontrolled conditions include but are not limited to the following: HIV not virally suppressed, COVID-19 infection, symptomatic malaria infection.
  • 3. Has any other condition that, in the opinion of the site investigator, would preclude verbal informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
  • 4. At time of enrollment, any known condition requiring routine antenatal care to take place at a location other than the study site CSCOM, e.g., Rh- negative status.
  • 5. At enrollment, reports either of the following: a) Participation in any research study involving drugs, vaccines, or medical devices during the current pregnancy, b) Expected to participate in other research studies involving drugs, vaccines, or medical devices for the duration of study participation
  • Sample Group 2: Midwives
  • Potential participants who do not provide verbal informed consent will not be included.
  • Sample Group 3: Pharmacists
  • Potential participants who do not provide verbal informed consent will not be included.
  • Sample Group 4: Family Members
  • Potential participants who do not provide verbal informed consent will not be included.

About Johns Hopkins Bloomberg School Of Public Health

The Johns Hopkins Bloomberg School of Public Health is a leading institution dedicated to advancing public health research and education. Renowned for its rigorous academic programs and commitment to improving global health outcomes, the School conducts innovative clinical trials that address pressing health challenges. With a focus on evidence-based practices, multidisciplinary collaboration, and community engagement, the Bloomberg School leverages its extensive resources and expertise to contribute to the development of effective public health interventions and policies. Through its research endeavors, the School aims to enhance population health and inform health policy both locally and globally.

Locations

Bamako, , Mali

Patients applied

0 patients applied

Trial Officials

Kristen M Hurley, PhD

Principal Investigator

Johns Hopkins Bloomberg School of Public Health

Lisa Noguchi, PhD

Study Director

Jhpiego

Samba Sow, MD

Study Director

Center for Vaccine Development - Mali

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials